आंतरिक चिकित्सा: खुली पहुंच
खुला एक्सेस

अमूर्त

Lipid Profile of Hemodialysis Patients at the CHU Sylvanus Olympio in Togo

Ouedraogo SM, Djibril MA, Balaka A, Baragou S, Tchamdja T, Djagadou K,and Agbetra A

Objective: To determine the atherosclerotic index in hemodialysis patients at the CHU Sylvanus Olympio in Togo with dyslipidemia. Methodology: It is about a descriptive cross-sectional study from 07 April to 7 June 2011 in the hemodialysis unit of the internal medicine department of the University Hospital of Lome-SO. Our study involved a population of chronic kidney disease (CKD) on dialysis for at least six months. Dyslipidemia was determined on serum lipid results of the various parameters obtained taking into account the biochemistry laboratory standards CHU-SO. Data were collected on a survey form and analyzed by the software Epi Info version 3.5 and Excel 2007.

Results: Our study involved sixty (60) chronic hemodialysis patients regularly followed up in the CHU-SO hemodialysis service. The study population consisted of 41 men and 19 women i.e., a sex-ratio of 2.15. The average age was 48.16 ± 13.63 years, ranging from 22 to 77 years. The age group 40 to 49 years was the most represented with 32.69% of cases (n=20). Sixty hemodialysis patients who participated in the study, 50 had at least one cardiovascular risk factor. Hypertension and diabetes mellitus were the most represented risk factors with rates of 75% and 23.3%. Patients had one cardiovascular risk factor (CVRF) in 64.98%, 2 CVRF in 13, 32%, 3 CVRF in 5.32% and no CVRF in 16.66%. The observed lipid disorders were represented by the total hypercholesterolemia (15%), the hypo HDLemia (26, 66%), the hyperLDLemia (12.40%), hypertriglyceridemia (46.66%). Twelve patients (20%) had mixed dyslipidemia. The index of atherogenic was above normal in most represented 36.66% in women (52.64%) than men (17.08%).

Conclusion: Dyslipidemia including hypertriglyceridemia and hypo-HDL cholesterol are common and potentially atherogenic in hemodialysis CHU-SO. The interest in the prevention and treatment of any systematic dyslipidemia in hemodialysis IRC prove necessary.